Jiangxi Fushine Stock Hits Day Low of CNY 13.99 Amid Price Pressure

Jiangxi Fushine Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 5.28% and hitting an intraday low of CNY 13.99. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by 3.63% during the same period. Over the past week, Jiangxi Fushine has seen a more pronounced downturn, with a 10.49% decrease, and a 13.49% drop over the past month. Despite a notable 75.59% increase over the past year, the company's year-to-date performance is down by 6.22%. The stock's long-term outlook appears challenging, with net sales declining at an annual rate of 8.27% and operating profit showing a significant negative trend. Financial metrics indicate a high debt-to-equity ratio of 59.26%, reflecting the company's financial leverage. Additionally, the return on capital employed (ROCE) stands at a low -12.02%, highlighting ongoing profitability concerns. As Jiangxi Fushine navigates these financial hurdles, its current market position remains under scrutiny within the pharmaceuticals and biotechnology sector.